L3VLUP
ProSign in

MYGN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MYGNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MYGN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMYGNVRTX
Q3 20206 holders, $99m31 holders, $21.9bn
Q4 20207 holders, $170m30 holders, $18.4bn
Q1 20215 holders, $195m31 holders, $15.4bn
Q2 20214 holders, $190m30 holders, $12.7bn
Q3 20213 holders, $191m35 holders, $10.1bn
Q4 20212 holders, $106m28 holders, $12.4bn
Q1 20222 holders, $102m23 holders, $16.1bn
Q2 20223 holders, $72m25 holders, $18.1bn
Q3 20223 holders, $193m22 holders, $18.4bn
Q4 20222 holders, $77m28 holders, $18.4bn
Q1 20235 holders, $388m26 holders, $21.4bn
Q2 20236 holders, $368m27 holders, $24.7bn
Q3 20232 holders, $101m33 holders, $24.3bn
Q4 20233 holders, $286m32 holders, $28.6bn
Q1 20243 holders, $332m31 holders, $29.8bn
Q2 20247 holders, $490m29 holders, $33.4bn
Q3 20245 holders, $456m27 holders, $33.5bn
Q4 20242 holders, $95m26 holders, $28.5bn
Q1 20253 holders, $56m21 holders, $35.4bn
Q2 20251 holders, $24m21 holders, $32.3bn
Q3 20251 holders, $33m22 holders, $25.9bn
Q4 20251 holders, $28m26 holders, $31.8bn
Q1 20262 holders, $25m25 holders, $31.8bn
Q2 20262 holders, $19m26 holders, $34.6bn
MYGN

Myriad Genetics Inc

Holders
1
Reported value
$24m
Buyers
1
Sellers
1

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 22 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only MYGN (1)

Glenview Capital Management LLC

Only VRTX (21)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →